|
| Press Releases |
|
 |
|
| Monday, September 2, 2024 |
|
|
Eisai Announces Status Relating to Acquisition of Own Shares |
| Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. more info >> |
|
| Thursday, August 22, 2024 |
|
|
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
| Wednesday, August 14, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of Alzheimer's disease (AD). more info >> |
|
| Tuesday, August 6, 2024 |
|
|
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation |
| Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows. more info >> |
|
| Wednesday, July 31, 2024 |
|
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
| Monday, July 29, 2024 |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Tuesday, July 16, 2024 |
|
|
エーザイ、ホスラブコナゾールのアジア・オセアニアにおけるライセンス契約を佐藤製薬と締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗真菌剤ホスラブコナゾールについて、真菌性疾患に対するアジア・オセアニアにおける開発および商業化に関するライセンス契約を佐藤製薬株式会社（本社：東京都、以下 佐藤製薬）と締結したことをお知らせします。 more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Droid Investment Funds Launches 'The 10 Fund Competition Institutional Capital vs. The Wisdom of the Crowd'
Apr 8, 2026 17:38 HKT/SGT
|
|
|
Guoyuan International: Essex Bio-Technology Embarks on Global Expansion, Maintains BUY Rating with Target Price of HK$6.84
Apr 8, 2026 17:20 HKT/SGT
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30: JST
|
|
|
Alpix Shares Early Beta Insights on AI-Assisted Trading and On-Chain Perpetuals Platform
Apr 8, 2026 15:30 HKT/SGT
|
|
|
正力新能2025年度業績實現爆發式增長 淨利潤增幅近8倍
Apr 8, 2026 11:44 HKT/SGT
|
|
|
三菱重工、NEDO懸賞金活用型プログラム「GENIAC-PRIZE」で第2位を受賞
Apr 8, 2026 11:30: JST
|
|
|
三菱重工グループのCrystal Mover Services、米国アトランタ国際空港のAPMシステム「ATL SkyTrain」の設備更新工事を受注
Apr 8, 2026 11:30: JST
|
|
|
MHI and Algomatic Win Second Place in the NEDO GENIAC‑PRIZE Program
Apr 8, 2026 12:03 JST
|
|
|
Heavyweight Endorsement from Top-tier Cornerstone Investors! Sigenergy (06656.HK) Launches IPO: Led by Temasek and Goldman Sachs, the AI Energy Storage Leader Ignites Hong Kong's New Stock Frenzy
Apr 8, 2026 11:01: JST
|
|
|
Heavyweight Endorsement from Top-tier Cornerstone Investors! Sigenergy (06656.HK) Launches IPO: Led by Temasek and Goldman Sachs, the AI Energy Storage Leader Ignites Hong Kong's New Stock Frenzy
Apr 8, 2026 10:01 HKT/SGT
|
|
|
頂級基石陣容重磅背書！思格新能源（06656.HK）啟動招股：淡馬錫、高盛領銜，AI 儲能領頭羊點燃港股新股熱潮
Apr 8, 2026 10:01 HKT/SGT
|
|
|
首程控股（0697.HK）分紅回購並舉 8年累計回饋股東約68.77億港元
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Shoucheng Holdings (0697.HK) Combines Dividends and Share Buybacks in Tandem, Returning Approximately HK$6.877 Billion to Shareholders Over Eight Years
Apr 8, 2026 08:00 HKT/SGT
|
|
|
Formerra宣佈全球提價
Apr 8, 2026 04:00 HKT/SGT
|
|
|
Formerra宣布全球提价
Apr 8, 2026 04:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
